DIEPPE, New Brunswick, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Pulmonem Inc.nand the Research Institute of the McGill University Health Centre todaynannounced that they have successfully started recruiting US-based npatients for the Phase 3 Clinical Trial (ClinicalTrials.gov Identifier: NCT04935476) of the promising COVID-19 therapeutic drug PULM-001.